Sandi Hita

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia

J. Radich, R. Stone, J. Lancet, 2018, American journal of hematology.

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

T. Zimmerman, M. Dhodapkar, P. Richardson, 2021, The Lancet. Haematology.

Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

M. Dhodapkar, P. Richardson, S. Rajkumar, 2020 .